Page last updated: 2024-08-17

histidine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

histidine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hochhaus, A; Lahaye, T; Müller, MC	1
Adamsky, K; Amariglio, N; Ashur-Fabian, O; Cohen, Y; Hardan, I; Nagler, A; Raanani, P; Rechavi, G; Trakhtenbrot, L	1

Other Studies

2 other study(ies) available for histidine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Article	Year
[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]. Deutsche medizinische Wochenschrift (1946), 2002, Oct-18, Volume: 127, Issue:42 Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Histidine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Pyrimidines; Selection, Genetic; Tyrosine	2002
Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis. Cell cycle (Georgetown, Tex.), 2007, Mar-01, Volume: 6, Issue:5 Topics: Apoptotic Protease-Activating Factor 1; Arginine; Blast Crisis; Gene Expression Regulation, Leukemic; Histidine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Point Mutation; Tumor Suppressor Protein p53	2007

Article

Year

[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].

Deutsche medizinische Wochenschrift (1946), 2002, Oct-18, Volume: 127, Issue:42

Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Histidine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Pyrimidines; Selection, Genetic; Tyrosine

2002

Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis.

Cell cycle (Georgetown, Tex.), 2007, Mar-01, Volume: 6, Issue:5

Topics: Apoptotic Protease-Activating Factor 1; Arginine; Blast Crisis; Gene Expression Regulation, Leukemic; Histidine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Point Mutation; Tumor Suppressor Protein p53

2007